Pharmacist-led steroid stewardship in inflammatory diseases: evaluating glucocorticoid use and patient outcomes

Clicks: 20
ID: 328213
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #108 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
PURPOSE: Glucocorticoids (GCs) are widely used in inflammatory diseases but are associated with significant adverse effects when used long term. Specialty pharmacists are uniquely positioned to monitor and optimize GC use through longitudinal patient management. This study aimed to characterize GC utilization and identify opportunities for pharmacist-led stewardship within a health-system specialty pharmacy. METHODS: This prospective, multi-center descriptive study implemented a pharmacist-driven GC questionnaire within CHRISTUS Specialty Pharmacy workflow. The questionnaire was incorporated into initial, and follow-up clinical assessments conducted every four to ten months. Eligible patients included those with inflammatory conditions receiving biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Data collected between October 1, 2025, and January 15, 2026, were analyzed using descriptive statistics. RESULTS: Among 688 patients, 17.4% reported active GC use. Mean duration of GC therapy was 112 days and was longer in patients receiving biologic DMARDs (184 days) compared to targeted synthetic DMARDs (105 days). GC use was most common in lupus (54.6%), rheumatoid arthritis (25.8%), and ulcerative colitis (25.5%). The majority of GC users had uncontrolled disease (63.9%), while minimal adverse effects were reported. CONCLUSION: Glucocorticoid use remains prevalent among patients receiving specialty therapies, particularly in those with uncontrolled disease. These findings highlight opportunities for pharmacist-led interventions focused on GC deprescribing, monitoring, and optimization of long-term outcomes.
Reference Key
openalex_W7212131993 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Vanessa Lopez, Alexandra Ritenour, Kiersi Harmon
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag276
URL
https://doi.org/10.1093/ajhp/zxag276
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.